Evidence map›Paper›PMID 41357761›Full record

ArticleHuman mutation2025

Integrated Genomic and Functional Characterization of Palmitoylation in Clear Cell Renal Cell Carcinoma.

Dong Zhang, Ke Zhang, Minghao Deng, Jiakang Ma, Jian Zhu, Shuijie Shen, Jianjun Xie, Chao Chen

Abstract read
In one paragraph

Article in Human mutation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dong ZhangDepartment of Urology, Nantong Hospital of Traditional Chinese Medicine, Affiliated Traditional Chinese Medicine Hospital of Nantong University, Nantong, China.
Ke ZhangDepartment of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.ORCID 0000-0001-8455-5553
Minghao DengDepartment of Urology, Nantong Hospital of Traditional Chinese Medicine, Affiliated Traditional Chinese Medicine Hospital of Nantong University, Nantong, China.
Jiakang MaHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Jian ZhuDepartment of Urology, Nantong Hospital of Traditional Chinese Medicine, Affiliated Traditional Chinese Medicine Hospital of Nantong University, Nantong, China.
Shuijie ShenClinical Medical Research Center, Nantong Hospital of Traditional Chinese Medicine, Affiliated Traditional Chinese Medicine Hospital of Nantong University, Nantong, China.ORCID 0000-0002-3018-8142
Jianjun XieDepartment of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.ORCID 0009-0007-3991-1046
Chao ChenDepartment of Urology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.ORCID 0009-0004-8483-3743

Funding

Regulatory T Cell Selection and SpecificityR01AI073731 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI CHATILA, TALAL AMINE, WILLIAMS, CALVIN B · 2009 to 2010
$986k
High Speed 1000 fps Angiography for X-ray Image Guided Cardiovascular InterventionsR01EB040435 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Swetadri Vasan Setlur Nagesh · 2026 to 2026
$601k
NIAID NIH HHS R01 AI073731NIBIB NIH HHS R01 EB040435
6 · The paper itself

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is a highly aggressive cancer with a poor prognosis. Palmitoylation, a posttranslational modification, plays a key role in regulating cancer progression and immune responses. However, its influence on ccRCC prognosis and immune therapy efficacy remains underexplored. Methods: Multiple publicly available ccRCC datasets were integrated and harmonized through batch effect correction. A prognostic model based on palmitoylation-related genes was constructed using a combination of 101 machine learning algorithms. Single-cell RNA sequencing was employed to analyze cellular heterogeneity within the tumor microenvironment. Genomic profiling, including tumor mutational burden (TMB), copy number variation (CNV), and tumor stemness, was conducted to identify genomic differences between the high- and low-risk groups. Immune infiltration levels were assessed using various algorithms to compare immune profiles across patient subgroups, while immune therapy responses were predicted using multiple prediction models. Experimental validation of ZDHHC18, a key gene in the prognostic model, was performed in ccRCC cell lines (786-O and Caki-1) to evaluate its impact on cell proliferation, migration, and invasion. Results: The palmitoylation-related prognostic model effectively stratified ccRCC patients into the high- and low-risk groups, with distinct differences in survival outcomes. Genomic analysis demonstrated higher TMB and CNV alterations in the high-risk group. Immune response predictions indicated that low-risk patients were more likely to benefit from immunotherapy. Additionally, ZDHHC18 was significantly upregulated in ccRCC tumor tissues, and its knockdown notably inhibited cell proliferation, migration, and invasion. Conclusion: Palmitoylation-related genes, particularly ZDHHC18, serve as promising prognostic biomarkers and predictive indicators for immune therapy in ccRCC. These findings offer new insights into ccRCC biology and highlight potential therapeutic targets for improving patient outcomes.

Indexed as

Carcinoma, Renal CellGenomicsKidney NeoplasmsLipoylationAcyltransferasesBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDNA Copy Number VariationsGene Expression Regulation, NeoplasticHumansMutationPrognosisTumor MicroenvironmentAcyltransferasesBiomarkers, Tumorclear cell renal cell carcinomaimmunotherapymachine learningpalmitoylationsingle-cell RNA sequencingZDHHC18

Identifiers

PMID41357761
PMCPMC12681404

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.